Abstract Purpose: N,N-Diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine (DPPE; tesmilifene) is thought to potentiate the antineoplastic effect of cytotoxic drugs. In a phase III randomized trial for metastatic breast cancer using doxorubicin with or without DPPE, addition of the latter resulted in a significant improvement in overall survival and a trend toward a difference in progression-free survival but, paradoxically, no difference in objective tumor response. Here we tested the hypothesis that DPPE targets breast tumor-initiating cells (TICs). Experimental Design: Human breast TICs from pleural effusions were identified as CD44 + :CD24 -/low cells by flow cytometry and functionally by their ability to form nonadherent spheres in culture. Mouse mammary TICs from two different models of breast cancer were identified as cells capable of initiating spheres in culture and secondary tumors following transplantation into the mammary gland of syngeneic mice. Results: We show that at physiologically attainable concentrations, treatment with DPPE alone reduced tumorsphere formation and viability of CD44 +
to potentiate the antineoplastic effect of cytotoxic drugs. In a phase III randomized trial for metastatic breast cancer using doxorubicin with or without DPPE, addition of the latter resulted in a significant improvement in overall survival and a trend toward a difference in progression-free survival but, paradoxically, no difference in objective tumor response. Here we tested the hypothesis that DPPE targets breast tumor-initiating cells (TICs). Breast cancer mortality is declining in Western countries primarily due to improvements in breast cancer screening and in the adjuvant treatment of early stage disease (1, 2) . Metastatic breast cancer remains an incurable illness for which few treatments have actually been shown to prolong survival. The most active chemotherapeutic agents in the treatment of metastatic breast cancer include the anthracyclines (e.g., doxorubicin) and the taxanes (e.g., docetaxel; ref. 3) . However, at best, only 50% of women treated with these agents will respond to therapy (4) . Thus, there is an urgent need for novel approaches to combat metastatic breast cancer.
There is growing evidence that cancer is organized in a hierarchy in which relatively rare tumor-initiating cells (TICs; also known as cancer stem cells) are capable of disseminating cancer, whereas the majority of tumor cells have lost this potential (5 -9) . This hierarchy has been first documented in acute myeloid leukemia (10, 11) . More recently, TICs (cancer stem cells) were identified in breast (12) and brain (13) cancers as well as other tumor types (14 -21) . Breast TICs express early epithelial markers such as the cell surface marker CD44, whereas nontumorigenic cells express CD24 (12) . CD44 + :CD24 -/low cells, but not CD24 + cells, sorted from malignant pleural effusions give rise to new tumors when injected into the fat pad of immunocompromised NOD/SCID mice (12) . Mouse models of cancer provide the power of mouse genetics, the availability of ample samples of genetically defined tumors and syngeneic transplantation assays. Several groups have recently identified TICs in mouse models of breast cancer (22 -25) . Our group has shown that TICs derived from Her2/Neu + as well as Wnt1-induced mammary tumors are capable of forming spheres under nonadherent conditions in a defined medium containing epidermal growth factor and fibroblast growth factor (23) . The tumorsphere-forming units (TFU) were indistinguishable by several criteria from TICs. Specifically, TFUs and TICs were identified in the same fraction of sorted cells, and cultured tumorspheres retained the differentiation capacity, cell surface markers, and tumorigenic potential of freshly isolated TICs. Thus, TFUs can be used as a surrogate for TICs in vitro.
Implicit in the cancer stem cell model is that targeted killing of TICs, rather than the bulk of nontumorigenic cells, may be curative (5, 6, 26) . However, TICs are not only rare but, in some instances, are also shown to be more resistant to radiation and cytotoxic therapy (27 -31) . The identification of agents that enhance the specificity of antineoplastic drugs toward TICs or that preferentially kill TICs is therefore of great interest.
The tamoxifen analogue N,N-diethyl-2-[4-(phenylmethyl)-phenoxy]ethanamine (DPPE; tesmilifene) has been implicated in the inhibition of histamine binding to CYP 3A4, a P450 isozyme that metabolizes several antineoplastic agents, as well as in the inhibition of p-glycoproteins involved in multidrug resistance (32 -34) . It is therefore thought that DPPE exerts its effect by potentiating the cytotoxicity of various antineoplastic drugs (35 -37) . The exact mechanism of action and the biological targets of DPPE are not known.
In a phase III randomized trial for metastatic breast cancer using doxorubicin with or without DPPE, it was observed that the addition of the latter resulted in a significant improvement in overall survival and a trend toward a difference in progression-free survival but, paradoxically, no difference in objective tumor response (38) . The effect of adding DPPE was not reproduced in the most recent trial of epirubicin plus cyclophosphamide +/-DPPE in naBve, previously untreated patients with metastatic breast cancer, possibly because of the excellent response by the EC arm alone, 6 although results from long-term follow-up are not yet available. Another trial with docetaxel +/-DPPE is ongoing (YM Biosciences, Inc.). DPPE has also been shown to have activity with mitoxantrone and prednisone in the treatment of hormone refractory prostate cancer (39) . Understanding the mechanism by which DPPE affects chemotherapy and overall survival may lead to improved therapy (39) . Using four different breast cancer models, we now show that treatment with DPPE alone preferentially kills TICs.
Materials and Methods
Patient recruitment and consent. Subjects with metastatic breast cancer and malignant pleural effusions were recruited from the clinical practices of a large, tertiary care cancer center under an Research Ethics Board -approved protocol. All patients provided written informed consent. Pleural fluid samples were obtained by standard thoracocentesis.
Enrichment of lineage-depleted breast cancer cells from pleural effusions. Pleural effusions were obtained and processed within 2 to 4 h after thoracocentesis. The samples were centrifuged at 1,000 rpm for 10 min and cell pellets were washed with HBSS plus 2% heat-inactivated fetal bovine serum (HIBS) and 2 mmol/L EDTA. Enrichment of epithelial cells was achieved using a negative selection kit StemSep (StemCell Technologies, Inc.). Briefly, 100 AL per 5 Â 10 7 cells of a cocktail containing biotinylated antibodies against human hematopoietic cells (CD2, CD14, CD16, CD38, CD45, and CD66) and glycophorin A were added. After 30-min incubation on ice, 60 AL of magnetic colloid were added and incubated for another 30 min on ice. Finally, the cells were passed trough magnetic columns and the supernatant containing epithelial cells was collected. The purified cells were cultured either as adherent monolayer with DMEM plus 10% fetal bovine serum or under nonadherent conditions (see below) plus penicillin/streptomycin.
Mice and PCR-based genotyping. MMTV-Wnt1 (40) and MMTV-Neu (41) transgenic mice, both on pure FvB background, were maintained in accordance with the Canadian Animal Care Council. The mice were genotyped by PCR analysis of DNA extracted from tail biopsies using the following primers: Wnt1, forward 5 ¶-GGACTTGCTTCTCTTCT-CATAGCC and reverse 5 ¶-CCACACAGGCATAGAGTGTCTGC; Neu, forward 5 ¶-CTAGGCCACAGAATTGAAAGATCT and reverse 5 ¶-gTAGG-TGGAAATTCTAGCATCATCC. Mice were sacrificed when tumors were 0.5 to 1 cm in diameter.
Enrichment of lineage-depleted epithelial cells from mouse mammary tumors. Mammary tumors were resected and minced by sterile razor blades, washed with HBSS plus 2% HIBS, and digested with 100 units/ mL collagenase/hyaluronidase (Stem Cell Technologies) for 30 min at 37jC. The resulting samples were passed through a 40-Am cell strainer (BD falcon) and centrifuged at 450 Â g for 5 min. The cell pellets were washed with HBSS + 2% HIBS, and lineage-negative (Lin -) epithelial cells were isolated using a negative selection EasySep Kit (StemCell Technologies). Briefly, 10 AL of FcR blocker were added per 1 Â 10 8 cells to prevent nonspecific interaction. Biotinylated antibodies (0.5 Ag/10 6 cells) against hematopoietic (anti-CD45 and anti-TER119; StemCell Technologies), stromal (anti-CD140a; Biosciences), and endothelial (anti-CD31; BD PharMingen) cells were added and incubated for 15 min at room temperature. Antibody conjugation to magnetic nanoparticles was achieved through 15-min incubation with EasySep Biotin Selection cocktail followed by 10 min with EasySep Magnetic Nanoparticles. An EasySep Magnetic device was used for 5 min to separate the Lin + cells that attached to the tube surface from the Lin -epithelial cells that remained in the supernatant. In vitro differentiation and immunocytostaining. Sorted CD44 + :CD24 -/low cells were plated on collagen 1 -coated coverslips (BD Biocoat) in growth medium (DMEM/F-12, 10% fetal bovine serum, 5 Ag/mL insulin, 1 Ag/mL hydrocortisone, 5 ng/mL epidermal growth factor, and penicillin/streptomycin) for 5 d and then differentiated for 24 h in medium containing DMEM/F-12, 5 Ag/mL insulin, 1 Ag/mL hydrocortisone, 3 Ag/mL prolactin, and penicillin/ 6 YM Biosciences, unpublished.
Translational Relevance
Previous models implicated N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine (DPPE; tesmilifene) in the potentiation of cytotoxicity by antineoplastic drugs. In a phase III randomized trial for metastatic breast cancer using doxorubicin with or without DPPE, addition of the latter resulted in a significant improvement in overall survival and a trend toward a difference in progression-free survival but, paradoxically, no difference in objective tumor response. We have now shown that continuous exposure to pharmacologically attainable doses of DPPE effectively kills tumor-initiating cells in four different models of breast cancer. Our results suggest that DPPE-based therapies should involve continuous or frequent administration of the drug. Furthermore, more potent DPPE derivatives with better specificity may be developed using the tumorinitiating cell^specific assays presented in our study. Finally, using these assays, combinatorial drug regimens with DPPE plus other antineoplastic agents with efficacy toward breast cancer subtypes should be assessed.
streptomycin. After fixation in 3.5% paraformaldehyde, cells were permeabilized in OPAS buffer (100 mmol/L PIPES, 1 mmol/L EGTA, 100 mmol/L KOH, 4% polyethylene glycol 8000, 0.1% Triton X-100 Tumorsphere formation assay. Enriched tumor cells from pleural effusions or MCF7 cells were seeded onto 6-or 24-well ultra-low attachment plates (Corning, Costar) in DMEM/F-12 Ham medium (Sigma) containing 10 ng/mL basic fibroblast growth factor (Sigma), 20 ng/mL epidermal growth factor (Sigma), 5 Ag/mL insulin (Sigma), and 0.4% bovine serum albumin and cultured at 37jC, 5% CO 2 . For mouse tumorspheres, Lin -mammary epithelial cells were plated on ultra-low attachment plates (Corning, Costar) in DMEM/F-12 Ham medium containing 20 ng/mL basic fibroblast growth factor (Sigma), 20 ng/mL epidermal growth factor, 4 Ag/mL heparin (Sigma), and B-27 supplement (1:50 dilution; Life Technologies). Medium was refreshed twice a week. Spheres were mechanically and enzymatically dissociated every 2 wk in 1Â (0.25%) trypsin-EDTA solution (Life Technologies) for 1 min at room temperature, followed by passing through 25-gauge needles seven times. The dissociated tumorsphere cells were added to 24-well ultra-low attachment plates at a cell density of 50,000 per well and treated as indicated in each figure.
Flow cytometry analysis and sorting. Human tumor cells were washed, counted, and resuspended in 50 AL (per 5 Â 10 5 cells) of HBSS plus 2% HIBS. Ten microliters of anti-CD44 [allophycocyanin (APC)] and antihuman CD24 (FITC; both from BD Biosciences) were added for 30 min on ice followed by two washes with HBSS/2% HIBS. The stained cells were washed again and resuspended in HBSS/2% HIBS containing the viability dye 7-amino-actinomycin D (BD Pharmingen) and passed through a cell strainer. For mouse mammary tumors, we used anti-CD49f conjugated to R-phycoerythrin (CD49f-PE) and anti-CD24 conjugated to FITC (CD24-FITC; BD Pharmingen). Flow cytometry analysis was done on a FACSCalibur (Becton Dickinson) and cell sorting was done on a FACSAria-13 color sorter (Becton Dickinson) at 30 psi, gating on the 7-amino-actinomycin D -negative (live) cells.
Annexin V and cell cycle analysis. Apoptosis was detected using PE-Annexin V (BD Biosciences). For pleural effusion cells, triple staining was carried out by first adding CD44-APC and CD24-FITC for 20 min on ice. The cells were washed with HBSS/2% HIBS and resuspended in Annexin V binding buffer. Annexin V-PE was added and incubated for 15 min at room temperature followed by flow cytometry. Cell cycle analysis was done on cells stained with propidium iodide/ RNase (BD Pharmingen). One-milliliter aliquots of cell suspensions were pelleted at 400 Â g for 5 min and fixed in 70% ethanol at 4jC for at least 60 min, and then f1 Â 10 5 cells were washed with 3 mL PBS (PBS) and stained with 500 AL propidium iodide/RNase. Samples were incubated for 15 min in the dark at room temperature and then analyzed by flow cytometry.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. For MCF7 monolayer cells, a total of 1,000 cells per well were seeded into 96-well plates and grown overnight in duplicate. After drug treatment, MTT (1 mg/mL) was added for 2 h at 37jC, followed by 100 AL DMSO overnight.
Colorimetric reading at 570 nm was done using a microplate reader (Molecular Devices). For MTT assay of tumorsphere cells, the protocol was modified as follows. Briefly, MTT was added to sphere cells and incubated for 2 h at 37jC. The supernatant including spheres was transferred to tubes and centrifuged at 500 Â g for 5 min. After aspirating the supernatant, the sphere cells were solubilized by adding 100 AL DMSO to liberate the dye.
Transplantation. Dissociated tumorsphere cells were resuspended in 10 AL serum-free DMEM/F-12 Ham medium, mixed at 1:1 ratio with 10 AL Matrigel (BD Bioscience), placed on ice, and then injected into # 4 mammary glands of syngeneic FvB mice or immunocompromised Rag1 -/-mice anesthetized with isoflurane. Sites of needle injection and incision were sealed with liquid bandage (NewSkin).
Statistical analysis. All data are represented as mean F SD. Two-tailed distribution Student's t test was carried out. P < 0.05 (*) and P < 0.01 (**) were considered statistically significant.
Results
DPPE inhibits the growth of MCF7 cells when cultured as tumorspheres but not as monolayer, whereas doxorubicin kills both. We first tested the effect of DPPE on the breast cancer cell line MCF7. The cells were plated under adherent conditions; treated with DPPE, doxorubicin, or both drugs; and the effect of cell viability was assessed by the colorimetric MTT assay, which measures mitochondrial reductase activity. Exposure of MCF7 cells to clinically attainable concentration of DPPE (5 Amol/L; refs. 42, 43) had only a minor effect, with a 20% reduction in total cell survival relative to cells treated with vehicle alone (dimethyformamide; Fig. 1A ). Under these conditions, clinically relevant concentrations of doxorubicin (0.05 and 0.1 Ag/mL) led to about 45% and 75% reductions in live MCF7 cells, respectively. Loss of viability was not enhanced by combined treatment with DPPE and doxorubicin. In this and other experiments, treatment with vehicle alone (dimethyformamide) did not have any significant effect on cell viability relative to no treatment (data not shown).
We next tested the effect of DPPE on the formation of MCF7 tumorspheres cultured in ultra-low attachment plates in defined medium containing epidermal growth factor and fibroblast growth factor. Under these nonadherent conditions, tumorspheres are formed by stem cells or TICs, whereas more differentiated cells tend to die by anoikis (44) . Thus, MCF7 cells were trypsinized to obtain single cells, plated under nonadherent conditions, and treated with the indicated drugs. The number of spheres in each culture was determined 7 days later. In contrast to the modest effect on MCF7 cells grown as monolayer (Fig. 1A, top) , DPPE (5 Amol/L) treatment reduced tumorsphere formation by 79.5 F 3.5% (mean F SD) relative to vehicle-treated cultures (Fig. 1A, bottom) . Treatment with both DPPE and doxorubicin had a moderate additive effect, leading to 88.6 F 0.86% suppression. To test whether the inhibition of MCF7 tumorsphere formation was cytostatic or cytotoxic, the cells were treated for 2 weeks under nonadherent conditions with the various drugs. The tumorspheres were then counted, trypsinized, and replated under the same conditions without drugs. As shown in Fig. 1B , the number of tumorspheres treated with DPPE continuously (four doses) dropped to 2 F 1.4% after 2 weeks of treatment (top) and the remaining cells did not form spheres when further cultured in drug free media (bottom). Thus, DPPE seems to exert a cytotoxic effect on TFUs. Notably, continuous exposure to DPPE was critical. A (Fig. 1C) and the fact that the cells have been clonally maintained in culture for an extended period of time. To corroborate our results, we analyzed the effect of DPPE on primary metastatic breast tumor cells from pleural effusions. TICs were previously identified in pleural effusions at a frequency of 1/100 to 1/1,000 in sorted CD44 + :CD24 -/low cells but at <1/10,000 in the CD44 + :CD24 + fraction (12). We Table  S1 ). The samples varied in their content of RBC, hematopoietic cells, and tumor epithelial cells. The hematopoietic fraction varied from f60% to >95% in different pleural effusion samples. To remove the hematopoietic cells, samples were passed through StemSep columns (StemCell Technologies) containing antihuman antibodies to the following antigens: CD2, CD14, CD16, CD38, CD45, CD66, and glycophorin A. Flow cytometry analysis revealed efficient depletion of hematopoietic cells ( Supplementary Fig. S1A) ; the remaining cells, which were larger in size, represented a more homogenous population of tumor epithelial cells (Supplementary Fig. S1B ). Following purification, tumor cells were cultured in adherent or nonadherent conditions. Five of the 12 samples had high RBC content, and attempts to recover tumor epithelial cells were unsuccessful. Of the remaining seven samples, two samples did not survive in culture; three samples (ER + ) survived as tumorspheres for about 8 to 12 weeks and were used to establish conditions for cell sorting (not shown); and two samples, T9 (ER + ) and T11 (ER -), gave rise to monolayer cultures that survived for several months and were further analyzed as -/low population. *, P < 0.05; **, P < 0.001, compared with dimethyformamide control. Flow cytometry analysis of the T9 and T11 primary pleural effusions grown as monolayer cultures revealed that both contained mostly CD44 + :CD24 -/low cells (Fig. 1C) . When plated in ultra-low attachment plates, the cells formed Research. (Fig. 1C) . To directly test the relationship between CD44 + :CD24 -/low and CD24 + cells and identify the cells capable of forming spheres, T9 and T11 primary cells grown as monolayer were isolated by fluorescence-activated cell sorting on the basis of CD24 and CD44 expression and then plated under adherent or nonadherent conditions (Fig. 2A) . The sorted CD44 + :CD24 -/low cells grew well as monolayer cultures and formed spheres in nonadherent conditions (Fig. 2B) Fig. 2A, right) . By contrast, the CD44 + :CD24 + cell population lost viability and remained CD24 + . Finally, to test the differentiation capacity of the sorted CD44 + :CD24 -/low tumor cells, they were seeded onto collagen 1 -coated coverslips, induced to differentiate, and immunostained with antibodies against smooth muscle actin, cytokeratin 14 (myoepithelial markers), and cytokeratin 18 (luminal marker). In four different sorting/ differentiation experiments, the CD44 + :CD24 -/low fractions differentiated to express one or more of these markers in >50% of the tumor cells (Supplementary Fig. S2 ). Thus, the CD44 + :CD24 -/low cell population exhibited limited self-renewal capacity under the conditions we used, gave rise to CD44 + : CD24 + cells, formed tumorspheres in culture, and had the ability to differentiate into distinct cell types.
DPPE suppresses CD44 + :CD24 -/low breast tumor cells from pleural effusions by inducing apoptotic death. We next investigated the effect of DPPE on the T9 and T11 primary pleural effusion cultures described above. The tumor cells were trypsinized to obtain single-cell suspension, plated in ultra-low attachment plates, and treated with vehicle alone (dimethyformamide) or physiologic attainable concentrations of doxorubicin (0.05 Ag/mL), DPPE (5 Amol/L), or both. Two weeks later, tumorsphere number and cell survival (MTT assay) were determined. Doxorubicin treatment reduced tumorsphere growth relative to vehicle-treated cultures by only 2-fold (Fig. 3A) . In contrast, cultures treated with DPPE or DPPE plus doxorubicin exhibited a 6-fold reduction in sphere formation and viability.
To determine which cell population was targeted by DPPE, the cultures were treated with the various drugs for 2 days and stained with fluorescent-conjugated CD24 and CD44 antibodies. Flow cytometry analysis revealed that doxorubicin -/low cell population. To investigate the mechanisms by which DPPE suppressed cell viability, the cultures were again treated with the various drugs for 2 days, and then unfixed cells were stained with FITC-CD24 and APC-CD44 as well as PE-Annexin V. Annexin V detects phosphatidylserine residues that translocate to the outer cell membrane during early stages of apoptosis. The intrinsic level of cell death for the CD44 + :CD24 -/low cells (13.96 F 0.48%) was slightly lower than that for the CD44 + :CD24 + cells (18.06 F 3.99%; Fig. 3D ). Doxorubicin treatment increased apoptotic cell death by f2-fold in both cell populations. In contrast, DPPE increased the rate of apoptosis in CD44 + :CD24 -/ low cells nearly 2-fold (26.38 F 5.01%; Fig. 3D , right) but did not increase apoptosis above background level in the CD24 + population (Fig. 3D, left) . Treatment with DPPE plus doxorubicin slightly increased overall cell death in the CD44 + :CD24 -/ low cell population (29.84 F 1.77%). Thus, DPPE induces apoptotic cell death in CD44 + :CD24 -/low cells. DPPE inhibits survival and cell cycle progression of Her2/neu and Wnt1 mammary tumor cells. We next analyzed mammary tumor cells derived from MMTV-Wnt1 and MMTV-Her2/neu transgenic mice, in which TICs can be functionally analyzed by transplantation into syngeneic mice (23) . We first tested the effect of DPPE on tumorsphere formation, apoptosis, and cell cycle progression in vitro. Primary tumors from MMTV-Wnt1 and MMTV-Neu were dissociated into single-cell suspension by enzymatic treatment and then immunodepleted for hematopoietic (CD45/Ter119 antibodies), endothelial (CD31 antibody), and stromal (CD140a antibody) cells (Supplementary Fig. S1C ). The Lin -tumor cells were then seeded into ultra-low attachment plates as described (23) . Primary tumorspheres from each tumor type were dissociated by light trypsinization and replated in the presence of drugs or vehicle alone. After 2 weeks of continuous treatment (four doses), the number of tumorspheres in each culture was assessed. As shown in Fig. 4A and B (top), DPPE treatment alone reduced the number of tumorspheres in both the Neu and WNt1 cultures. The effect of DPPE was more pronounced in the Neu-induced tumors (<2 F 0.71% relative to dimethyformamide control) than in the Wnt1-induced tumors (39.5 F 1.41%). The tumorspheres were then dissociated and replated in the absence of drugs; 2 weeks later, tumorspheres were either counted or subjected to MTT assay to measure viability. Very few tumorspheres arose in the DPPE-treated Neu cultures whereas f23% of Wnt1 tumorspheres survived (relative to vehicle-treated cultures). Similar inhibition of tumorsphere cell viability was observed with the MTT assay ( Fig. 4A and B,  bottom) . Examples of the cultures treated with the various drugs are shown in Fig. 4C and D.
We next determined the sensitivity of Neu tumorspheres to different doses and concentrations of DPPE over a 2-week period. Continuous treatment with physiologically relevant concentration of DPPE (i.e., four changes over 2 weeks; 5 Amol/mL) produced the strongest effect (Fig. 5A) . At a higher concentration (10 Amol/mL), DPPE suppressed tumorsphere formation even more efficiently (not shown). At lower drug concentrations or doses, the effect of DPPE on tumorsphere formation was significantly reduced. To determine whether DPPE induces apoptotic cell death in mouse mammary tumor cells as it does in human breast tumor cells from pleural effusions (Fig. 3) , tumorspheres were dissociated, replated under nonadherent conditions, and treated with the indicated drugs for different time periods. The cells were then collected and stained with 7-amino-actinomycin D, which is excluded by live cells, plus Annexin V, which specifically labels apoptotic cells, and analyzed by flow cytometry. Continuous exposure to DPPE induced massive cell death in Her2/neu tumors, whereas doxorubicin, at the concentrations we used, had only a moderate effect (Fig. 5B) . Kinetic analysis revealed that the induction of apoptosis by DPPE was modest (50 F 5.8%) in the first 3 days of treatment and dramatically increased >5-fold after 2 weeks of treatment (Fig. 5C) .
In parallel experiments with Wnt1-induced tumor cells, DPPE treatment for 2 weeks increased the level of apoptosis by only 2.2-fold, compared with 1.5-fold induced by doxorubicin (F0.19; Fig. 5D ). In MMTV-Wnt1 -induced mammary tumors, TICs and TFUs are found in the CD24 + :CD49f + doublepositive cell population (23, 24) . 7 To test the effect of DPPE on tumor cells by marker analysis, monolayer MMTV-Wnt1 tumor cells were treated for 2 weeks with the various drugs and then subjected to flow cytometry analysis with CD24 and CD49f. The percentage of CD24 + :CD49f + cells in primary tumors was initially f38% (data not shown) but was reduced to f3% after 2 weeks in monolayer culture (Fig. 5E) Fig. 5E and F) . Thus, the tumorsphere formation assay, Annexin V staining, and marker analysis indicate that (a) Neu tumor cells are more sensitive than Wnt1 tumor cells to DPPE; (b) both Neu and Wnt1 tumor cells are significantly more sensitive to DPPE than to doxorubicin; and (c) continuous treatment with DPPE is required for targeted killing of TFUs/TICs.
To test the effect of DPPE on cell cycle progression, tumorspheres treated for 1 week with the indicated drugs were stained with propidium iodide to label DNA content and analyzed by flow cytometry. The percentage of cells in S/G 2 /M phases was f15.92 F 2.94% and 8.96 F 0.21% for Wnt1 and Neu tumorspheres, respectively ( Supplementary Fig. S3 ). Exposure to 0.05 Ag/mL doxorubicin had little effect on cell cycle distribution of either culture. In contrast, treatment with DPPE suppressed the S/G 2 /M phases by 33 F 3.35% and 59 F 13.43% in Wnt1 and Neu tumorspheres, respectively, suggesting that DPPE preferentially eliminates cycling cells.
Direct killing of Neu and Wnt1 TICs by DPPE. Whereas tumorsphere formation can be used as a surrogate for tumor initiation, the ultimate test for TICs is their ability to form secondary tumors after transplantation into recipient mice. Thus, to directly test the effect of DPPE on TICs, Neu or Wnt1 tumorspheres were dissociated and replated in the presence of the various drugs under nonadherent conditions. After 2 weeks, the cultures were trypsinized and counted by trypan blue exclusion assay; 50, 100, or 250 live cells were mixed with Matrigel and injected into the mammary glands (#4) of syngeneic FvB female mice. Tumor incidence after 3 and 5 months is depicted in Figure 6 and Table 1 . Treatment of Wnt1 tumorspheres with DPPE or doxorubicin reduced tumor incidence to 4/12 and 2/12, respectively, relative to vehicle-treated cultures (7/12 tumors after injections of 250 or 100 cells). Treatment with both drugs completely abolished tumor initiation (0/12; Table 1 ).
With Neu tumorsphere cells, doxorubicin treatment alone reduced but did not completely eliminate tumor incidence 3 months after transplantation (4/18 total injections of 250 or 50 cells) as compared with vehicle-treated cells (15/20) . In contrast, DPPE-treated tumorsphere cells did not give rise to tumors at this stage (0/18; Table 1 ). Figure 6 shows representative recipient mice 3 months after transplantation with Neu tumor cells pretreated with the indicated drugs. After 2 additional months (i.e., 5 months posttransplantation), five tumors appeared in the DPPE-treated cells. The latency of tumor formation following DPPE treatment was 2.6-fold longer than following doxorubicin treatment. Specifically, the latencies for tumor formation in the dimethyformamide-, doxorubicin-, and DPPE-treated groups were 63.6 F 13.7, 51.7 F 3.5, and 137.2 F 11.7 days, respectively. Combined treatment of the Neu tumor cells with DPPE plus doxorubicin completely abolished TICs (0/18 injections in total). We conclude that DPPE effectively kills TICs and that combined treatment with DPPE plus doxorubicin cooperates to eradicate both Wnt1 and Neu TICs.
Discussion
Here we show that DPPE (tesmilifene) can act as a single agent to target TICs. It induces apoptotic death in TICs when administered alone and, in certain contexts, cooperates with doxorubicin to further kill these tumorigenic cells. Our observation that DPPE can directly target TICs questions previous models that implicated DPPE in the potentiation of cytotoxicity by antineoplastic drugs (33) . These models were strengthened by the observation that the molecular structure of DPPE includes a tertiary amine, phenyl rings, and carbonyl group often found in p-glycoprotein inhibitors (47 -49) . However, DPPE also enhances cytotoxicity of multidrug resistance -negative tumor cells, and the enhancement (or cooperation) with other drugs is not accompanied by increased intracellular concentration of these drugs (42) . In fact, it was hypothesized that DPPE may activate, rather than inhibit, p-glycoproteins (33) . We propose that the effect of DPPE as a single agent has been overlooked in previous experiments because TICs were not assayed directly. As we observed, DPPE alone had a minor effect on MCF7 cells grown as monolayer, in which only a very small fraction of the cells are TICs. By testing for TICs directly, for example by quantifying the ability of MCF7 breast tumor cells to form tumorspheres under nonadherent conditions, we were able to show efficient and direct killing of TICs by DPPE. In addition to MCF7 cells, specific killing of TICs by DPPE was observed with two independent metastatic breast tumors from breast cancer patients with malignant pleural effusions. Finally, we showed that DPPE specifically killed TICs from MMTV-Neu and MMTV-Wnt1 mammary tumors as tested by both in vitro and in vivo assays. In aggregate, our data suggest that DPPE directly targets TICs. This model may explain the significant improvement in overall survival and progression-free survival observed in the doxorubicin plus DPPE arm despite no objective difference in tumor response (38) , as targeted killing of rare TICs may reduce additional metastasis and improve overall survival without significantly affecting the bulk of metastatic tumors.
The most parsimonious model for the cooperation between DPPE and doxorubicin is that their individual effect on TICs is simply accumulative. Each drug kills TICs, albeit with different efficacy, and combined treatment with both drugs has an additive effect. Another level of cooperation is suggested from data in Table 1 showing that treatment with DPPE increases the latency for tumor formation by 2.6-fold relative to doxorubicin. The late onset of these tumors may also be explained if the cancer stem cell hierarchy is not as stable as is commonly thought (i.e., if non-TICs can revert to TICs by genetic or epigenetic changes after a prolonged period of time following transplantation; ref. 50). Thus, DPPE and doxorubicin may cooperate by targeting different cells: DPPE preferentially targets TICs; doxorubicin preferentially kills non-TICs (with the potential to revert); and combined treatment eliminates both cell types, hence any tumorigenic potential. Additional analysis will be required to address the stability of the cancer stem cell hierarchy and its effect on chemotherapy in the contexts of drugs, such as DPPE, that target TICs.
We have shown that continuous exposure to high, pharmacologically attainable doses of DPPE (5 Amol/L) effectively kills TICs in vitro. The need for continuous exposure may be the hallmark of drugs that target TICs as these cells are thought to undergo slow self-renewal. Our results suggest that DPPE-based therapies should involve continuous or frequent administration of the drug. This is notably a challenge given the side effect of the drugs at the current dose (38) , but may be overcome with a better understanding of the pharmacokinetics of DPPE. Alternatively, more potent DPPE derivatives with better specificity may be developed. The identification of the cellular target(s) of DPPE and the affected biological process/pathway are therefore of paramount importance. . We have found that the metastatic breast tumors from pleural effusions and HER2/ Neu + mammary tumors were highly sensitive to DPPE, Wnt1 TICs were less sensitive, whereas MCF7 sensitivity depended on culture conditions (very low as monolayer; high as spheres). The high sensitivity of HER2/Neu + mammary tumors to DPPE is consistent with the high frequency of TICs in this tumor subtype (23, 31, 52) . Consistent with the differential sensitivity of different tumor types to DPPE, stratification of the clinical results from the National Cancer Institute of Canada MA.19 trial revealed that ER-negative tumors responded better than the entire tumor set (33) . Given the high sensitivity of the Neu + tumor cells to DPPE (Figs. 4 -6 + and ER + tumors may be tested in combinations with anthracyclin plus herceptin, lapatinib plus capecitabine, or hormonal therapies, respectively.
In conclusion, using four different breast tumor models, we showed that DPPE directly kills TICs and, in certain contexts, cooperates with doxorubicin to further eliminate these tumorigenic cells. A continuous exposure to 5 Amol/L concentration of the drug is required for optimal results. Thus, DPPE may serve as a prototype TIC-specific inhibitor with available clinical data.
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